Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

921 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-11

Study Completion Date

2020-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single site blinded RCT of 920 pregnant women with singleton gestation designed to compare the Carpenter-Coustan and IADPSG criteria for diagnosing gestational diabetes. Maternal metabolic profiles and infant growth will be assessed at randomization and at one year postpartum.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gestational Diabetes Diagnostic Methods

NCT01540396

Gestational Diabetes

COMPLETED NA

Randomizing Two Gestational Diabetes Screening Methods in a Diverse HMO

NCT02266758

Gestational Diabetes Obesity Pregnancy

UNKNOWN NA

An RCT to Evaluate Incidence, Cost and Clinical Outcomes Using 75 vs 100g. Screening Methods for Gestational Diabetes

NCT00295659

Gestational Diabetes

COMPLETED

One Step Versus Two Step Approach for Gestational Diabetes Mellitus Screening

NCT03073330

Gestational Diabetes

UNKNOWN NA

Daily Versus Every Other Day Glucose Monitoring in Gestational Diabetes Mellitus

NCT04857073

Gestational Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impaired glucose metabolism (gestational diabetes (GDM) and mild hyperglycemia) that occurs during pregnancy is associated with an increased risk for pregnancy complications and is also an early indication of long-term metabolic dysfunction leading to diabetes and cardiovascular disease. In the US, GDM is diagnosed using a two-step screening and diagnostic approach. The International Association of Diabetes and Pregnancy Study Group (IADPSG) proposed a one-step diagnostic approach that broadens the definition of GDM by lowering the cutoff values to include women with milder forms of hyperglycemia, who would have screened normal under the current two-step approach. The goal of these recommendations is better identification of women at risk for pregnancy complications and long-term metabolic dysfunction, but it results in a significant increase in the prevalence of GDM. The NIH GDM Consensus Development Conference committee does not recommend changing from the current two-step screening/diagnostic approach to the IADPSG one-step diagnostic approach without trials demonstrating that increasing the number of women diagnosed as having GDM results in better outcomes. We aim to 1) conduct a "real world" randomized controlled trial (RCT) to determine differences in short-term perinatal health outcomes between the two predominant GDM screening approaches, and 2) prospectively follow the mothers to examine their metabolic risk profiles and the growth of their infants at 1 year postpartum. Based on a pilot study, we propose a single site blinded RCT of 920 pregnant women ages 18-45 years without a diagnosis of diabetes, with a singleton pregnancy (18-24 wks gestation). Participants will have a non-fasting 1 hour 50 gm glucose challenge test (GCT) performed between 24-28 weeks' gestation. Women with 50 gm GCT results \< 200 mg/dL will be randomized to receive either a fasting 2 hour 75 gm oral glucose tolerance test (OGTT) or a 3 hour 100 gm OGTT. GDM will be diagnosed using the IADPSG criteria for women receiving the 75 gm OGTT and Carpenter-Coustan criteria for women receiving the 100 gm. Participants and their physicians will be informed of the diagnosis of GDM, but blinded to the specific test results and diagnostic criteria. Participants with GDM will receive treatment from their primary provider. Questionnaires will be used to assess participants' and physicians' views on GDM testing. Metabolic profiles will be assessed at randomization and at a year postpartum. The primary outcome measure is large-for-gestational age fetal growth. The rationale for this RCT is that this is a unique opportunity to compare the two methods. At the end of the study, we will know whether women diagnosed at lower glucose levels with the IADPSG criteria are more likely to have adverse perinatal outcomes. We hypothesize that using IADPSG diagnostic criteria will result in greater detection of women with impaired glucose metabolism and treating these women will reduce adverse perinatal outcomes and prevent long-term metabolic dysfunction. This study will provide level A data for endorsing universal screening guidelines for GDM by major organizations and implementation into clinical care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gestational Diabetes Pregnancy Glucose Intolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3 hour 100 gm OGTT (CC Criteria)

Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of \>130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.

Group Type ACTIVE_COMPARATOR

Gestational diabetes screening with fasting 3 hour 100 gm

Intervention Type DIAGNOSTIC_TEST

Participants receive fasting 3 hour 100 gm oral glucose tolerance test

2 hr 75 gm OGTT (IADPSG Criteria)

Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.

Group Type ACTIVE_COMPARATOR

Gestational diabetes screening with fasting 2 hour 75g

Intervention Type DIAGNOSTIC_TEST

Participants receive fasting 2 hour 75 gm oral glucose tolerance test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gestational diabetes screening with fasting 3 hour 100 gm

Participants receive fasting 3 hour 100 gm oral glucose tolerance test

Intervention Type DIAGNOSTIC_TEST

Gestational diabetes screening with fasting 2 hour 75g

Participants receive fasting 2 hour 75 gm oral glucose tolerance test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnancy between 18-24 weeks of gestation
* Singleton gestation
* Planning to deliver at Magee-Womens Hospital, Pittsburgh, Pennsylvania

Exclusion Criteria

* Preexisting type 1 or 2 diabetes
* Diabetes diagnosed at less than 24 weeks gestational age (GA)
* Multiple gestations ( e.g. twins or triplets)
* Hypertension requiring medications
* Corticosteroid (IM, oral or IV) use in the 30 days prior to enrollment
* Major congenital anomaly with anticipated preterm delivery due to maternal or fetal indications \< 28 wks GA
* Inability to complete the glucose testing before 30 completed weeks GA
* Advanced HIV( on medications that cause hyperglycemia), severe liver disease, gastric bypass surgery or other illness/surgeries that preclude them from drinking the glucola solution.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes